Arcturus Therapeutics Holdings Inc. Share Price
Equities
ARCT
US03969T1097
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.55 USD | +1.45% | +2.19% | -15.79% |
Sales 2024 * | 147M 11.77B | Sales 2025 * | 241M 19.3B | Capitalization | 715M 57.22B |
---|---|---|---|---|---|
Net income 2024 * | -68M -5.44B | Net income 2025 * | 3M 240M | EV / Sales 2024 * | 2.39 x |
Net cash position 2024 * | 364M 29.14B | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.96 x |
P/E ratio 2024 * |
-10.2
x | P/E ratio 2025 * |
-154
x | Employees | 180 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.25% |
Latest transcript on Arcturus Therapeutics Holdings Inc.
1 day | +1.45% | ||
1 week | +2.19% | ||
Current month | -21.38% | ||
1 month | -19.20% | ||
3 months | -16.30% | ||
6 months | +44.22% | ||
Current year | -15.79% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Payne
CEO | Chief Executive Officer | 52 | 28/02/13 |
Andrew Sassine
DFI | Director of Finance/CFO | 59 | 31/08/19 |
Chief Operating Officer | 45 | 31/12/12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Edward W. Holmes
BRD | Director/Board Member | 83 | 31/08/19 |
James F. Barlow
BRD | Director/Board Member | 65 | 26/05/18 |
Peter Farrell
CHM | Chairman | 81 | 26/05/18 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 26.55 | +1.45% | 275,687 |
25/04/24 | 26.17 | -3.00% | 526,939 |
24/04/24 | 26.98 | -3.40% | 266,354 |
23/04/24 | 27.93 | +3.22% | 314,125 |
22/04/24 | 27.06 | +4.16% | 327,983 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.79% | 715M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ARCT Stock